(Q39661604)

13 September 2017

title

Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology (English)

1 reference

13 September 2017

1 reference

Conrad M Tobert

1

1 reference

13 September 2017

Robert G Uzzo

series ordinal

2

1 reference

13 September 2017

Christopher G Wood

series ordinal

3

1 reference

13 September 2017

Brian R Lane

series ordinal

4

1 reference

13 September 2017

publication date

20 January 2012

1 reference

13 September 2017

1 reference

13 September 2017

volume

31

1 reference

13 September 2017

issue

7

1 reference

13 September 2017

page(s)

1316-1320

1 reference

13 September 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Metastatic renal cell carcinoma: many treatment options, one patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Sunitinib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Sorafenib in advanced clear-cell renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Surgical resection of renal cell carcinoma after targeted therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.12.014

10.1016/J.UROLONC.2011.12.014

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference